Black Hawk Acquisition Corporation Units

Vesicor Therapeutics, a biotech company developing p53-based cancer therapeutics, announced the appointment of Michael Tolentino, M.D. as Chief Executive Officer effective March 17, 2026. Tolentino, a serial entrepreneur with over 20 years of biotech experience, succeeds founder Luo Feng who transitions to Chief Scientific Officer. The leadership...

Vesicor Therapeutics, a biotechnology company focused on p53-based cancer therapeutics, has entered into a business combination agreement with Black Hawk Acquisition Corporation to create a public company advancing its drug candidate.

DANVILLE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Black Hawk Acquisitions Corporation (NASDAQ: BKHAU), please note that the second paragraph reference to Mr. Ginsberg meeting "the independent director standards of The Nasdaq Stock Market" has been removed. The corrected release fol...

DANVILLE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Black Hawk Acquisition Corporation (NASDAQ: BKHAU, the "Company") announced today the appointment of Mr. Jonathan Ginsberg, age 33, to serve as a director of the Company and its Chief Operating Officer.

DANVILLE, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Black Hawk Acquisition Corporation (NASDAQ: BKHAU, the “Company”) announced today that it has closed its initial public offering of 6,900,000 units at $10.00 per unit. Each unit consists of one share of common stock and one-fifth (1/5) of one right to receive one share of common stock upo...